Assembly Biosciences (NASDAQ:ASMB) Releases Earnings Results, Beats Expectations By $0.11 EPS

Assembly Biosciences (NASDAQ:ASMB) released its earnings results on Thursday. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11, Zacks reports. Assembly Biosciences had a negative return on equity of 4.70% and a negative net margin of 8.98%.The company had revenue of $8.21 million during the quarter, compared to analyst estimates of $9.27 million.

Assembly Biosciences Trading Down 3.8%

ASMB traded down $1.19 during midday trading on Friday, reaching $29.74. 143,418 shares of the company’s stock traded hands, compared to its average volume of 141,040. The firm has a fifty day moving average of $28.67 and a two-hundred day moving average of $30.55. Assembly Biosciences has a 52 week low of $11.64 and a 52 week high of $39.71.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ASMB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Monday, April 20th. Wall Street Zen raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 29th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Monday. Finally, Guggenheim upped their price target on Assembly Biosciences from $39.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Assembly Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ASMB. Bank of America Corp DE raised its position in shares of Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,823 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new position in shares of Assembly Biosciences in the 4th quarter worth approximately $228,000. Virtus Investment Advisers LLC bought a new position in shares of Assembly Biosciences in the 4th quarter worth approximately $251,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Assembly Biosciences in the 3rd quarter worth approximately $282,000. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.